CellCept (mycophenolate mofetil, MMF) maintenance immunosuppression in liver transplant recipients with long-term follow-up post-transplantation for non-autoimmune liver disease - a prospective, randomized, multicenter trial.

Trial Profile

CellCept (mycophenolate mofetil, MMF) maintenance immunosuppression in liver transplant recipients with long-term follow-up post-transplantation for non-autoimmune liver disease - a prospective, randomized, multicenter trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Ciclosporin; Mycophenolate mofetil; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jan 2009 Additional trial identifier CEL350 added as reported by ClinicalTrials.gov.
    • 05 Jan 2009 Planned end date changed from 1 Oct 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top